Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

被引：0
|
作者：
Coffey, David G. [1 ,2 ]
Landgren, Ola [3 ]
Xu, Yuexin [1 ]
Kazandjian, Dickran [4 ]
Pugh, Trevor J. [5 ]
Gnjatic, Sacha [6 ]
Warren, Edus H. [1 ,2 ]
Green, Damian J. [1 ,2 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Seattle, WA USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
[4] NCI, Ctr Canc Res, Lymphoid Malignancies Branch, Multiple Myeloma Program,NIH, Bethesda, MD 20892 USA
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Icahn Sch Med Mt Sinai, Human Immune Monitoring Ctr, New York, NY 10029 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126222
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4367
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Chromosomal instability and acquired drug resistance in multiple myeloma
    Wang, Wang
    Zhang, Yi
    Chen, Ruini
    Tian, Zhidan
    Zhai, Yongpin
    Janz, Siegfried
    Gu, Chunyan
    Yang, Ye
    ONCOTARGET, 2017, 8 (44) : 78234 - 78244
  • [32] Multiple Myeloma: Available Therapies and Causes of Drug Resistance
    Pinto, Vanessa
    Bergantim, Rui
    Caires, Hugo R.
    Seca, Hugo
    Guimaraes, Jose E.
    Helena Vasconcelos, M.
    CANCERS, 2020, 12 (02)
  • [33] Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
    Yang, Wen-Chi
    Lin, Sheng-Fung
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [34] Overexpression of aldose reductase in liver cancers may contribute to drug resistance
    Lee, KWY
    Ko, BCB
    Jiang, AR
    Cao, DL
    Chung, SSM
    ANTI-CANCER DRUGS, 2001, 12 (02) : 129 - 132
  • [35] ANTIANGIOGENIC PROPERTIES OF IMMUNOMODULATORY DRUG LENALIDOMIDE IN ENDOTHELIAL CELLS OF PATIENTS WITH ACTIVE MULTIPLE MYELOMA
    De Luisi, A.
    Ferrucci, A.
    Di Pietro, G.
    Berardi, S.
    Basile, A.
    Ria, R.
    Ribatti, D.
    Coluccia, A. M. L.
    Maffia, M.
    Ranieri, G.
    Paradiso, A.
    Guarini, A.
    Vacca, A.
    CANCER TREATMENT REVIEWS, 2010, 36 : S106 - S106
  • [36] Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: Rationale and clinical experience
    Chanan-Khan, Asher Alban
    Lee, Kelvin
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S163 - S169
  • [37] Multiple mechanisms contribute to drug resistance in rat liver epithelial cells expressing polyoma virus middle T antigen
    Carson, C
    Testolin, L
    Dhanraj, KN
    Walker, PR
    Sikorska, M
    FASEB JOURNAL, 1999, 13 (07): : A1435 - A1435
  • [38] Multiple myeloma and persistence of drug resistance in the age of novel drugs
    Krishnan, Sabna Rajeev
    Jaiswal, Ritu
    Brown, Ross D.
    Luk, Frederick
    Bebawy, Mary
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (01) : 33 - 50
  • [39] Overcoming drug resistance by targeting protein homeostasis in multiple myeloma
    Moscvin, Maria
    Ho, Matthew
    Bianchi, Giada
    CANCER DRUG RESISTANCE, 2021, 4 (04) : 1028 - 1046
  • [40] The role of NOTCH pathway in multiple myeloma associated drug resistance
    Garavelli, Silvia
    Lazzari, Elisa
    Colombo, Michela
    Platonova, Natalia
    Palano, Maria Teresa
    Baccianti, Francesco
    Galletti, Serena
    Neri, Antonino
    Crews, Leslie
    Jamieson, Catriona
    Chiaramonte, Raffaella
    CANCER RESEARCH, 2017, 77
12345